KR20240157067A - 미디엄- 또는 마크로-시클릭 벤질-치환된 헤테로사이클 유도체 및 관련 용도 - Google Patents
미디엄- 또는 마크로-시클릭 벤질-치환된 헤테로사이클 유도체 및 관련 용도 Download PDFInfo
- Publication number
- KR20240157067A KR20240157067A KR1020247032615A KR20247032615A KR20240157067A KR 20240157067 A KR20240157067 A KR 20240157067A KR 1020247032615 A KR1020247032615 A KR 1020247032615A KR 20247032615 A KR20247032615 A KR 20247032615A KR 20240157067 A KR20240157067 A KR 20240157067A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- alkyl
- pharmaceutically acceptable
- present disclosure
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263315438P | 2022-03-01 | 2022-03-01 | |
| US63/315,438 | 2022-03-01 | ||
| US202363439477P | 2023-01-17 | 2023-01-17 | |
| US63/439,477 | 2023-01-17 | ||
| PCT/US2023/014275 WO2023167925A1 (en) | 2022-03-01 | 2023-03-01 | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240157067A true KR20240157067A (ko) | 2024-10-31 |
Family
ID=85772026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247032615A Pending KR20240157067A (ko) | 2022-03-01 | 2023-03-01 | 미디엄- 또는 마크로-시클릭 벤질-치환된 헤테로사이클 유도체 및 관련 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20250236629A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4486748A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025507852A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240157067A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119110802A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023228830A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3245204A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002576A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315237A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024010608A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202400606A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023167925A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| WO2022207935A1 (en) | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| EP4680611A1 (en) | 2023-03-16 | 2026-01-21 | Takeda Pharmaceutical Company Limited | Macrocyclic heterocycle compounds and use thereof |
| JP2026518313A (ja) | 2023-06-01 | 2026-06-04 | ハー・ルンドベック・アクチエゼルスカベット | スピロ大環状オレキシン2受容体アゴニスト |
| CN122374291A (zh) | 2023-12-12 | 2026-07-10 | 爱杜西亚药品有限公司 | 作为食欲素受体调节剂的芳基砜及砜酮衍生物 |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
| US20260144795A1 (en) | 2024-11-27 | 2026-05-28 | H. Lundbeck A/S | Spiromacrocyclic orexin 2 receptor agonists |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US10428023B2 (en) | 2017-08-03 | 2019-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| PE20211700A1 (es) | 2019-01-31 | 2021-09-01 | Takeda Pharmaceuticals Co | Compuesto heterociclico y su uso |
| KR20260083444A (ko) * | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| CN116635393A (zh) * | 2020-09-03 | 2023-08-22 | 欧瑞夏治疗有限公司 | 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途 |
-
2023
- 2023-03-01 WO PCT/US2023/014275 patent/WO2023167925A1/en not_active Ceased
- 2023-03-01 KR KR1020247032615A patent/KR20240157067A/ko active Pending
- 2023-03-01 EP EP23713207.1A patent/EP4486748A1/en active Pending
- 2023-03-01 IL IL315237A patent/IL315237A/en unknown
- 2023-03-01 TW TW112107384A patent/TW202400606A/zh unknown
- 2023-03-01 JP JP2024551975A patent/JP2025507852A/ja active Pending
- 2023-03-01 MX MX2024010608A patent/MX2024010608A/es unknown
- 2023-03-01 CA CA3245204A patent/CA3245204A1/en active Pending
- 2023-03-01 CN CN202380037293.8A patent/CN119110802A/zh active Pending
- 2023-03-01 AU AU2023228830A patent/AU2023228830A1/en active Pending
-
2024
- 2024-08-28 US US18/817,943 patent/US20250236629A1/en active Pending
- 2024-08-29 CL CL2024002576A patent/CL2024002576A1/es unknown
-
2025
- 2025-04-11 US US19/177,396 patent/US20250289828A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202400606A (zh) | 2024-01-01 |
| US20250289828A1 (en) | 2025-09-18 |
| JP2025507852A (ja) | 2025-03-21 |
| MX2024010608A (es) | 2024-09-23 |
| CL2024002576A1 (es) | 2025-01-10 |
| EP4486748A1 (en) | 2025-01-08 |
| AU2023228830A1 (en) | 2024-09-12 |
| CA3245204A1 (en) | 2023-09-07 |
| CN119110802A (zh) | 2024-12-10 |
| US20250236629A1 (en) | 2025-07-24 |
| WO2023167925A1 (en) | 2023-09-07 |
| IL315237A (en) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12503475B2 (en) | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | |
| JP7811578B2 (ja) | 中環状または大環状ベンジル置換複素環誘導体およびオレキシン-2受容体アゴニストとしてのそれらの使用 | |
| AU2023228830A1 (en) | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses | |
| JP7443625B2 (ja) | ビシクロヘプタンピロリジンオレキシン受容体アゴニスト | |
| AU2024350399A1 (en) | Ras-pi3k inhibitors for the treatment of cancer and immunological diseases | |
| IL275058B1 (en) | Sulphonyl urea derivatives as nlrp3 inflammasome modulators | |
| JP7862437B2 (ja) | オレキシン-2受容体アゴニスト活性を有する置換されるアミド大環状化合物 | |
| EP3891157A1 (en) | 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels | |
| CN119156375A (zh) | 双环杂环衍生物和相关用途 | |
| WO2022207935A1 (en) | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists | |
| TW202309051A (zh) | 食慾素受體促效劑及其用途 | |
| TW202321272A (zh) | 肽衍生物和作為食慾激素促效劑之相關用途 | |
| JP2024520395A (ja) | 置換される縮合二環式大環状化合物および関連のある治療方法 | |
| TW202417432A (zh) | 抗菌化合物 | |
| JP2025516719A (ja) | Nlrp3を阻害するためのオキソインドリニルアミド誘導体およびその使用 | |
| WO2022147302A1 (en) | 4-phenyl-indole derivatives and related uses | |
| EA052303B1 (ru) | Средне- или макроциклические производные бензилзамещенного гетероцикла и связанные с ними применения | |
| TW202530205A (zh) | 經取代之芳基磺醯胺及其組合物及用途 | |
| WO2025106644A1 (en) | Heterocyclic compounds as inhibitors of alpha-v beta-1 integrin | |
| CA3260373A1 (en) | MACROCYCLICAL BCL6 DEGRADING AGENTS | |
| TW202604484A (zh) | 經取代之芳基磺醯胺及其組合物及用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |